Dual GLP-1 and glucagon receptor agonists

1. Dual GLP-1 and glucagon receptor agonists decrease triglyceride in humans (-0.28 mmol/L [95% CI -0.50, -0.06]).

   “Compared with selective GLP-1R agonists, dual GLP-1R/GCGR agonists were associated with a greater reduction in triglycerides (-0.28 mmol/L [95% CI -0.50, -0.06]).”

   Human trialcompared with selective GLP-1R agonists

   Cardiometabolic Effects of Dual GLP-1 and Glucagon Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials

   Diabetes care·21 Aug 2026

More on Triglyceride

1. Dual GLP-1 and glucagon receptor agonists decrease body weight in humans (-7.44% [95% CI -9.44, -5.43]).

   “Dual GLP-1R/GCGR agonists significantly reduced body weight compared with placebo (-7.44% [95% CI -9.44, -5.43]; -7.27 kg [95% CI -9.28, -5.27]).”

   Human trialcompared with placebo≥12 weeksn = 6,611

   Cardiometabolic Effects of Dual GLP-1 and Glucagon Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials

   Diabetes care·21 Aug 2026

More on Body weight